Gene-expression assays have produced a huge step forward in identifying patients who are likely to benefit from adjuvant chemotherapy but there is still a long way to go in the more specific targeting of treatment
In her Keynote Lecture at ESMO Breast Cancer 2022, Prof. Sibylle Loibl looks at neoadjuvant therapy and the fertility and pregnancy issues facing young women with breast cancer
The value of genomic testing is being increasingly demonstrated and will evolve over time
A greater understanding of the complexity of breast cancer, in all its forms, is key to better patient selection, new target development and improved outcomes, says Prof. Fabrice André
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
In the NeoTRIPaPDL1 study, combining information from biomarker analysis at baseline and during treatment was informative on clinical benefit
Phase I/II trials also show these compounds have more convenient dosing and are well tolerated in both the early and advanced settings
The efficacy and overall good tolerability of cyclin-dependent kinase (CDK) 4/6 inhibitors have led to a change in the therapeutic algorithm of HR-positive/HER2-negative advanced breast cancer and established these compounds as the gold standard option for any patient with metastatic disease, except those with visceral crisis.
Final overall survival results from the KEYNOTE-355 study confirm immune checkpoint inhibitors as the first-line treatment of choice in women with metastatic or relapsing disease
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
